Objective: To probe into the mechanism of Ephedra Herba and Amygdalus Communis Vas couplet medicines (EHACV) in the treatment of bronchopneumonia based on network pharmacology. Methods: Based on the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP)

the chemical compositions of EHACV and correspondent targets were obtained. The targets of bronchopneumonia were obtained from the comparative toxicogenomics database (CTD) and GeneCards databases. Then the targets of chemical compositions were mapped to the targets of bronchopneumonia to predict the targets of EHACV acting on bronchopneumonia. The compositions-targets network and protein-protein interactions (PPI) network were established by using the Cytoscape software. Gene ontology enrichment and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis were performed based on DAVID database. Results: A total of 48 kinds of active compounds were screened out

and 145 drug targets were obtained after deduplication. And 108 common targets associated with bronchopneumonia were obtained

including AKT1

MAPK3

JUN and VEGFA. KEGG enrichment analysis mainly involved interleukin (IL)-17 signaling pathway

tumor necrosis factor (TNF) signaling pathway

vascular endothelial growth factor (VEGF) signaling pathway

etc. Conclusion: The network pharmacology method is used to predict the possible disease targets and biological processes of EHACV in the treatment of bronchopneumonia

which provides ideas and basis for the verification of the molecular mechanism.